About Mustang Bio (NASDAQ:MBIO)
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel cancer immunotherapy products based on the chimeric antigen receptor engineered T (CAR T) cell technology. The company's CAR T product candidates include MB-101, a IL13Ra2 CAR T cell program which is in Phase I clinical study for glioblastoma; and MB-102, a CD123 CAR T cell program to treat acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm; and MB-106, a CD20 CAR T cell program that is in Phase I clinical study for the treatment of B cell non-Hodgkin lymphoma. It also develops MB-104, a CS1 CAR T, which is in Preclinical study for multiple myeloma and light chain amyloidosisy; MB-103, a human epidermal growth factor receptor 2 CAR T that is in Preclinical study to treat glioblastoma multiforme and metastatic breast cancer to brain; and MB-105, a prostate stem-cell antigen CAR T for prostate and pancreatic cancers. The company has a partnership agreement with the City of Hope National Medical Center and Fred Hutchinson Cancer Research Center to develop proprietary CAR T therapies across various cancers. It also holds a license agreement with Harvard University; and a research collaboration agreement with Beth Israel Deaconess Medical Center for the development of CRISPR/Cas9-enhanced CAR T therapies for the treatment of cancer. The company was incorporated in 2015 and is based in New York, New York. Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MBIO
CUSIPN/A
Phone781-652-4500
Debt
Debt-to-Equity RatioN/A
Current Ratio17.00%
Quick Ratio17.00%
Price-To-Earnings
Trailing P/E Ratio-11.85
Forward P/E Ratio-8.95
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.27 per share
Price / Book3.90
Profitability
EPS (Most Recent Fiscal Year)($0.75)
Net Income$-31,280,000.00
Net MarginsN/A
Return on Equity-31.64%
Return on Assets-30.28%
Miscellaneous
Employees6
Outstanding Shares27,100,000
Mustang Bio (NASDAQ:MBIO) Frequently Asked Questions
What is Mustang Bio's stock symbol?
Mustang Bio trades on the NASDAQ under the ticker symbol "MBIO."
How were Mustang Bio's earnings last quarter?
Mustang Bio (NASDAQ:MBIO) posted its earnings results on Thursday, March, 29th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.02. View Mustang Bio's Earnings History.
What price target have analysts set for MBIO?
2 brokers have issued 1 year price objectives for Mustang Bio's stock. Their predictions range from $18.00 to $18.00. On average, they expect Mustang Bio's stock price to reach $18.00 in the next twelve months. View Analyst Ratings for Mustang Bio.
Who are some of Mustang Bio's key competitors?
Some companies that are related to Mustang Bio include Biohaven Pharmaceutical (BHVN), Athenex (ATNX), CytomX Therapeutics (CTMX), Zai Lab (ZLAB), Uniqure (QURE), MacroGenics (MGNX), Access Pharmaceuticals (ABEO), Alder BioPharmaceuticals (ALDR), Flexion Therapeutics (FLXN), Amphastar Pharmaceuticals (AMPH), Assembly Biosciences (ASMB), Inflarx (IFRX), Lexicon Pharmaceuticals (LXRX), Amarin (AMRN) and Mirati Therapeutics (MRTX).
Who are Mustang Bio's key executives?
Mustang Bio's management team includes the folowing people:
- Mr. Michael S. Weiss, Exec. Chairman (Age 52)
- Dr. Manuel Litchman M.D., Pres, Chief Exec. Officer & Director (Age 64)
- Mr. Brian K. Achenbach, Interim CFO, VP of Fin. & Corp. Controller (Age 53)
- Dr. Knut Niss, Chief Technology Officer
- Dr. Sadik Kassim, Chief Scientific Officer
Has Mustang Bio been receiving favorable news coverage?
Media coverage about MBIO stock has been trending somewhat positive on Thursday, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Mustang Bio earned a media sentiment score of 0.25 on Accern's scale. They also gave press coverage about the company an impact score of 46.31 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
How do I buy shares of Mustang Bio?
Shares of MBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mustang Bio's stock price today?
One share of MBIO stock can currently be purchased for approximately $8.86.
How big of a company is Mustang Bio?
Mustang Bio has a market capitalization of $261.75 million. The company earns $-31,280,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. Mustang Bio employs 6 workers across the globe.
How can I contact Mustang Bio?
Mustang Bio's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected]
MarketBeat Community Rating for Mustang Bio (MBIO)
MarketBeat's community ratings are surveys of what our community members think about Mustang Bio and other stocks. Vote "Outperform" if you believe MBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
Mustang Bio (NASDAQ:MBIO) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Mustang Bio in the last 12 months. Their average twelve-month price target is $18.00, suggesting that the stock has a possible upside of 103.16%. The high price target for MBIO is $18.00 and the low price target for MBIO is $18.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | N/A |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | N/A |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $18.00 | $18.00 | $18.00 | N/A |
| Price Target Upside: | 103.16% upside | 64.68% upside | 64.68% upside | N/A |
Mustang Bio (NASDAQ:MBIO) Consensus Price Target History
Mustang Bio (NASDAQ:MBIO) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 12/21/2017 | CIBC | Initiated Coverage | Outperform -> Outperform | $18.00 | Medium |  |
| 12/20/2017 | Oppenheimer | Initiated Coverage | Outperform | $18.00 | Medium | |
(Data available from 4/26/2016 forward)
Mustang Bio (NASDAQ:MBIO) Earnings History and Estimates Chart
Mustang Bio (NASDAQ:MBIO) Earnings Estimates
2018 EPS Consensus Estimate: ($1.00)
2019 EPS Consensus Estimate: ($1.10)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2018 | 1 | ($0.23) | ($0.23) | ($0.23) |
| Q2 2018 | 1 | ($0.24) | ($0.24) | ($0.24) |
| Q3 2018 | 1 | ($0.25) | ($0.25) | ($0.25) |
| Q4 2018 | 1 | ($0.28) | ($0.28) | ($0.28) |
| Q1 2019 | 1 | ($0.28) | ($0.28) | ($0.28) |
| Q2 2019 | 1 | ($0.28) | ($0.28) | ($0.28) |
| Q3 2019 | 1 | ($0.26) | ($0.26) | ($0.26) |
| Q4 2019 | 1 | ($0.28) | ($0.28) | ($0.28) |
Mustang Bio (NASDAQ MBIO) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 3/29/2018 | Q4 2017 | ($0.24) | ($0.22) | | | View | N/A | |
| 11/14/2017 | Q3 2017 | | ($0.27) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Mustang Bio (NASDAQ:MBIO) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Mustang Bio (NASDAQ MBIO) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 2.83%
Mustang Bio (NASDAQ MBIO) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Mustang Bio (NASDAQ MBIO) News Headlines
| Source: |
|
Mustang Bio (NASDAQ:MBIO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Mustang Bio (NASDAQ:MBIO) Income Statement, Balance Sheet and Cash Flow Statement
Mustang Bio (NASDAQ MBIO) Stock Chart for Thursday, April, 26, 2018
Loading chart…
